SOLARA Q4 FY26 Guidance vs Delivery (SOLARA Management Mirror)

Did SOLARA's management deliver what it guided? Guidance vs actual performance and tone changes across recent earnings calls, as of the Q4 FY26 (Mar-2026 Qtr) concall.

  • SOLARA Financials
  • SOLARA Shareholding Pattern
  • SOLARA Earnings Documents
  • SOLARA Announcements
  • SOLARA Corporate Actions
  • SOLARA Bulk, Block & Insider Deals
  • SOLARA Delivery Data
  • SOLARA Earnings Concalls
  • Market Timeline
  • Concall Monitor
  • Company Research
  • Earnings Monitor
  • Upcoming Results
  • Sector Monitor
  • Sector Performance
  • Bulk & Block Deals
  • Delivery Data
  • FII & DII Activity
  • Market Indices
  • Plans & Pricing

Solara Active Pharma Sciences Ltd (SOLARA) Q4FY26 Management Mirror - Mar-2026 Qtr

Strategic Review & Restructuring

The Ibuprofen strategic review and Vizag facility roadmap are now expected to conclude by the Sep'26 Qtr, while the polymers and CRAMS carve-out remains paused pending this outcome. Expectations evolved from a planned CRAMS demerger (Sep'25 Qtr) to a delayed spin-off pending an Apr'26 Qtr decision (Dec'25 Qtr), which has now been further extended by two quarters. [Status: Downgraded]

4 more themes on the ELITE plan.

  • SOLARA Q4FY26 Concall Summary
  • SOLARA Q4FY26 Concall Transcript
  • SOLARA Q3FY26 Management Mirror (Dec-2025 Qtr)
  • SOLARA Q1FY27 Management Mirror (Jun-2026 Qtr)